Nasdaq

CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.

CytoSorb is the only approved therapy to remove ticagrelor in the European Union, and is intended to address a major unmet medical need of potentially life-threatening postoperative bleeding in ...
Nasdaq

U.S. CTC Registry Shows High Survival Using CytoSorb In Critically Ill COVID-19 Patients On ECMO

(RTTNews) - CytoSorbents Corporation (CTSO) on Wednesday announced topline CTC (CytoSorb Therapy in COVID-19) Registry results showing high survival rate in critically ill COVID-19 patients on ...
Seeking Alpha

Cytosorbents: Looking Closer At 'Survival Benefit' Of Cytosorb In Septic Shock

Given that the results described above seem highly significant and positive, the following statements from the lead author in the PR seemed reasonable. Dr. Willem P. Brouwer, MD PhD, from Erasmus ...
Business Insider

CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19

MONMOUTH JUNCTION, N.J., Sept. 14, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery ...
Business Insider

CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress

MONMOUTH JUNCTION, N.J., April 28, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...
FOX31 Denver

CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms

BAD HOMBURG V.D. HÖHE, GERMANY and PRINCETON, N.J., Aug. 2, 2022 /PRNewswire/ -- Fresenius Medical Care (NYSE: FMS; Frankfurt Stock Exchange: FME) and CytoSorbents Corporation (NASDAQ: CTSO) have ...